Joshua Feder, MD

RESEARCH UPDATE

SSRIs and Hydroxyzine for Avoidant/Restrictive Food Intake Disorder (ARFID)?

October 1, 2022

Dr. Feder, author of this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

Clinicians use olanzapine, mirtazapine, and other appetite-inducing medications off label to treat ARFID, but with little research to support their use. This study unpacks the potential role of medications in treating comorbid symptoms associated with ARFID.

Note from the Editor-in-Chief

July 1, 2022

Joshua Feder, MD

Josh Feder, MD.

Editor-in-Chief of The Carlat Child Psychiatry Report.

In 2015 at my first Graphic Medicine conference (www.graphicmedicine.org), clinicians and patients spoke about the daily hurt people experience with fat shaming, some to the point of suicidality. It’s one thing to see it but another to fight it. Our interview with Dr. Sarah Nutter helps us combat weight bias.

Note From the Editor-in-Chief

October 30, 2020

Joshua Feder, MD

Josh Feder, MD Dr. Feder has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

With a surging pandemic and cultural turmoil, we are all working as best we can. At Carlat, we are striving to give you what you need to keep going. Every clinician needs to prepare for disasters, even if that is mainly knowing how to support your own patients when disaster...

Note From the Editor-in-Chief

June 26, 2019

Joshua Feder, MD

Joshua Feder, MD

In this double issue, we tackle a range of questions. First, does TMS help kids and teens with depression? Is it safe? Since many clinics are advertising TMS, we thought it was worth a close look.

FDA Approves Adhansia XR

June 11, 2019

Talia Puzantian, PharmD, BCPP and Joshua Feder, MD

Talia Puzantian, PharmD, BCPP Joshua Feder, MD Drs. Puzantian and Feder have disclosed that they have no relevant financial or other interests in any commercial companies pertaining to this educational activity.

In this article we discuss a newly FDA-approved formulation for ADHD. Adhansia XR, is a new formulation of extended-release methylphenidate approved by the FDA for the treatment of ADHD in patients 6 years and older.

First Non-Drug Treatment Approved by FDA for Treating Children With ADHD

June 11, 2019

Talia Puzantian, PharmD, BCPP and Joshua Feder, MD

Talia Puzantian, PharmD, BCPP Joshua Feder, MD Drs. Puzantian and Feder have disclosed that they have no relevant financial or other interests in any commercial companies pertaining to this educational activity.

In the article we discuss the effectiveness and safety of the first non-drug treatment for ADHD in kids. The FDA has recently granted medical device approval for its external Monarch Trigeminal Nerve Stimulation (eTNS) System for treating kids with ADHD ages 7–12 who are not currently taking medications.

Note From the Editor-in-Chief

March 13, 2019

Joshua Feder, MD

Joshua Feder, MD

This double issue was long in the making. We contacted a number of experts in the world of trauma, from Jeff Max on traumatic brain injury to Suzan Song on helping refugees. We also spoke with Stuart Shanker about what we could learn from his experience in developing mass education on self-regulation in children. And as promised, we have responded to the recent reports of increased mortality in children taking “higher” doses of antipsychotic medications.

Note From the Editor-in-Chief

January 1, 2019

Joshua Feder, MD

Joshua Feder, MD Editor-in-Chief, The Carlat Child Psychiatry Report

For our 2019 issue on anxiety, we spoke with Dr. Moira Rynn at Duke about the concept of anxiety as a pervasive symptom that cuts across diagnostic categories. We are focused on anxiety as a target symptom that happens every day, but what are the data for medication treatment?

Note From the Editor-in-Chief

November 1, 2018

Joshua Feder, MD

Joshua Feder, MD Editor-in-Chief, The Carlat Child Psychiatry Report

In this issue we tackle a range of challenges, including differentiating ADHD from bipolar disorder, understanding suicide risk in college students, managing assertions about the safety of weed, and assessing and treating violent behavior in our patients.

Note From the Editor-in-Chief

September 1, 2018

Joshua Feder, MD

Joshua Feder, MD Editor-in-Chief, The Carlat Child Psychiatry Report

In this issue, we look at the complex relationship between bullying and suicidality and offer a range of ideas on how to help your patients with this all-too-common problem, both in the office and in advocating for your patients, with resources to boot.